Barclays Initiates Coverage on Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) with Overweight

Barclays analysts initiated coverage on Bristol-Myers Squibb Company PFD CONV 2 (OTC:BMYMP) with a Overweight rating on February 20, 2026.

Bristol-Myers Squibb Company PFD CONV 2 operates in the Healthcare sector. The stock currently trades at $1002.93 with a market capitalization of $1815.9B.